MedTrace Logo

Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV)

NCT00681889 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2012-11-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the effectiveness and safety of ranibizumab (Lucentis) in treatment of corneal neovascularization.

Conditions

  • Corneal Neovascularization

Interventions

DRUG

Ranibizumab

10 Patients will receive treatment (Ranibizumab)

Sponsors & Collaborators

  • Reza Dana, MD

    lead OTHER

Principal Investigators

  • Reza Dana, M.D., MPH · Massachusetts Eye and Ear Infirmary

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2009-09-30
Completion
2010-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00681889 on ClinicalTrials.gov